Summary of Ashland's Q4 Fiscal Year 2025 Earnings Call

1Key Financial Results and Metrics

Sales: $478 million, down 8% year-over-year, primarily due to portfolio optimization; excluding these actions, sales were down 1%.

Adjusted EBITDA: $119 million, a 4% decrease year-over-year, with an 11 million impact from portfolio optimization; on a comparable basis, EBITDA increased by 5%, with margins expanding to approximately 25%.

Adjusted EPS: $1.08, down 14% from the prior year, impacted by a higher effective tax rate.

Free Cash Flow: $52 million, reflecting disciplined capital spending and working capital management; total liquidity at over $800 million.

Net Leverage: 2.9x, expected to improve to mid-2s following a $103 million tax refund.

2Strategic Updates and Business Highlights

Business Unit Performance:

Life Sciences: Sales of $173 million, down 10% due to divestitures; however, steady demand in high-value pharma applications led to an adjusted EBITDA margin of 32%.

Personal Care: Sales of $151 million, down 7% due to divestitures; however, on a comparable basis, sales grew by 5%, driven by strong performance in biofunctional actives and microbial protection.

Specialty Additives: Sales of $131 million, down 9%, but achieved the highest margins of the year at 22.1%.

Intermediates: Sales of $33 million, down 8%, with continued pricing and volume pressures leading to a 15.2% margin.

Transformation Efforts: Portfolio optimization and restructuring are complete, with a focus on high-value consumer-facing markets. A $60 million manufacturing optimization program is underway, with $5 million in savings realized this year and $18 million projected for next year.

3Forward Guidance and Outlook

Fiscal 2026 Guidance:

Expected sales between $1.835 billion and $1.905 billion, representing organic growth of 1% to 5%.

Adjusted EBITDA projected between $400 million and $430 million, with free cash flow conversion of 50%.

Adjusted EPS expected to grow in double digits, driven by operational improvements and lower depreciation.

Strategic Priorities: Focus on advancing innovation, scaling globalized platforms, and driving cost and productivity initiatives.

4Bad News, Challenges, or Points of Concern

Volume and Pricing Pressures: Continued competitive intensity, particularly from Chinese competitors, is affecting pricing and volume, especially in the Intermediates and Specialty Additives segments.

Market Conditions: Uncertain macroeconomic environment with potential headwinds from interest rates and housing turnover impacting demand in North America.

Delayed Benefits from Optimization: The full impact of the manufacturing optimization program is taking longer than expected to materialize, with some benefits contingent on a recovery in China.

5Notable Q&A Insights

Volume Recovery: Life Sciences and Personal Care showed volume gains, but the coatings business in China remains weak. Future volume growth is contingent on market recovery.

Nutrition Segment: Weakness in the nutrition side is expected to recover in FY 2026, with recent share gains already impacting results positively.

Capital Allocation: The company is balancing investments in organic growth with maintaining leverage, with a focus on high-quality growth investments.

Innovation Pipeline: Expected to contribute $15 million in incremental sales in FY 2026, with a focus on core technologies and new product launches. Overall, Ashland's Q4 results reflect a resilient performance amidst challenging market conditions, with strategic initiatives aimed at long-term growth and profitability. However, the company faces ongoing competitive pressures and macroeconomic uncertainties that could impact future performance.